MedTrace Logo

Epidemiology of Congenital Heart Disease in France

NCT04740177 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450000

Last updated 2021-03-16

No results posted yet for this study

Summary

Congenital heart disease (CHD) is the leading cause of birth defects, with an incidence of 0.8%. Since the 1980s, France has been a pioneer in neonatal CHD surgery (Pr. Fontan, Pr. Lecomte, Pr. Serraf, etc.), in prenatal diagnosis, and in interventional cardiac catheterization.

Actually, first children operated for complex CHD have reached adulthood and a new epidemiology of CHD is emerging. Currently, one of the public health challenges is the need to maintain appropriate follow-up and to avoid disruption of care during the transition from adolescence to adulthood. Thus, the national health authorities (DGOS) recently certified a national network of expert centers for complex CHD (M3C).

In addition, under the leadership of the French Society of Cardiology, the sub-specialty of Pediatric and Congenital Cardiology has been recognized.

However, while North American and North European countries have published their updated data on the main indicators of CHD morbidity and mortality, no study has reported epidemiology of CHD in France.

Currently, available data are approximate, estimating that 200,000 children and 250,000 adults would be living in France with a CHD. Nevertheless, no information is available on hospitalizations, type of CHD, their follow-up, possible disruption in care, and morbidity and mortality in patients with CHD in France. This epidemiological study will use the national health insurance hospital database to answer these questions.

Conditions

  • Congenital Heart Disease

Sponsors & Collaborators

  • National Reference Center for Complex Congenital Heart Disease, Marie-Lannelongue Medical and Surgical Center, Le Plessis Robinson

    collaborator UNKNOWN

  • University Hospital, Bordeaux

    collaborator OTHER

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Pascal AMEDRO, MD-PhD · UH MONTPELLIER

  • Sarah Cohen · • Centre Médico-Chirurgical Marie-Lannelongue, Le Plessis Robinson

  • Jean-Benoit Thambo · University Hospital, Bordeaux

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-12-01
Completion
2020-12-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04740177 on ClinicalTrials.gov